

References

I-226

1. Monjuvi (tafasitamab-cxix), for injection, for intravenous use [package insert]. Morphosys US Inc. Boston, MA. Revised 06/2021.
2. Salles G, Duell J, Gonzalez Barca E, et al. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. 2020;21(7):978-988.
3. NCCN: National Comprehensive Cancer Network (NCCN). Tafasitamab-cxix. NCCN Drugs and Biologics Compendium®. 2024.
4. Clinical Pharmacology™ Compendium. 2024. Tampa FL: Gold Standard, Inc. Tafasitamab-cxix.
5. Duell J, Maddocks KJ, González-Barca E, et al. Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. *Haematologica*. 2021;106(9):2417-2426.
6. Micromedex DrugDex Compendium®. 2024. Tafasitamab-cxix.
7. Tafasitamab-cxix In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated May 24, 2021.